Breast Cancer

Click on the tabs above by breast cancer type to view active trials.
Protocol #SponsorProtocol Title
NCT02132949Hoffmann-La Roche
WO29217
A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-Stage Breast Cancer.
Northwest Georgia Oncology Centers (NGOC)  is actively engaged in clinical trials advancing the treatment of breast cancer offered for various stages and types.  We divide breast cancers into three main groups based on molecular phenotypes: estrogen receptor positive, HER2 receptor positive and “triple negative” breast cancers.
Protocol #SponsorProtocol Title
NCT02132949


Hoffmann-La Roche
WO29217
A Multi-Center, Multi-National, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients with HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer

NCT02132949MacroGenics
CP-MGAH22-04
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
Northwest Georgia Oncology Centers (NGOC) is actively engaged in clinical trials advancing the treatment of breast cancer offered for various stages and types. We divide breast cancers into three main groups based on molecular phenotypes: estrogen receptor positive, HER2 receptor positive and “triple negative” breast cancers.NGOC offers multiple trials in HER2 receptor positive breast cancer. The recently FDA-approved HER2 antibody pertuzumab (Perjeta®) is being investigated in Early Breast Cancer, Advanced Breast Cancer, and in combination with hormonal therapy in Hormone-receptor Positive/HER2 receptor positive advanced breast cancer.  In addition, NGOC is conducting trials with the investigational agent, TDM-1 in advanced HER2 receptor positive breast cancer.
Protocol #SponsorProtocol Title
NCT02340221

Hoffmann-La Roche
GO29058, 2014-003185-25
A Phase III, Double-Blind, Placebo Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)
NCT02278120

Novartis Pharmaceuticals
CLEE011E2301
A Phase III Randomized, Double-Blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
NCT02000622
AstraZeneca
D0819C00003, 2013-005137-20
A Phase III, Open Label, Randomized, Controlled, Multi-center Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations. (OlympiAD)
Northwest Georgia Oncology Centers (NGOC) is actively engaged in clinical trials advancing the treatment of breast cancer offered for various stages and types. We divide breast cancers into three main groups based on molecular phenotypes: estrogen receptor positive, HER2 receptor positive and “triple negative” breast cancers.In hormone receptor positive breast cancer, trials are currently being conducted with new agents designed to enhance hormone receptor sensitivity.
Protocol #SponsorProtocol Title
NCT02425891

Hoffmann-La Roche
WO29522, 2014-005490-37
A Study of MPDL3280A in Combination with Nab-Paclitaxel Compared with Placebo With Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
NCT02340221

Hoffmann-La Roche
GO29058, 2014-003185-25
SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
NCT02000622

AstraZeneca
D0819C00003, 2013-005137-20
A Phase III, Open Label, Randomized, Controlled, Multi-center Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)
NCT02278120
Novartis Pharmaceuticals
CLEE011E2301
A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer (MONALEESA-7)
NCT01997333

Celidex Therapeutics
CDX011-04
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients with Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
NCT02132949MacroGenics
CP-MGAH22-04
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
Northwest Georgia Oncology Centers (NGOC) is actively engaged in clinical trials advancing the treatment of breast cancer offered for various stages and types. We divide breast cancers into three main groups based on molecular phenotypes: estrogen receptor positive, HER2 receptor positive and “triple negative” breast cancers.
Protocol #SponsorProtocol Title
NCT02425891

Hoffmann-La Roche
WO29522, 2014-005490-37
A Study of MPDL3280A in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
NCT02000622

AstraZeneca
D0819C00003, 2013-005137-20
A Phase III, Open Label, Randomized, Controlled, Multi-center Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations. (OlympiAD)
NCT01997333

Celidex Therapeutics
CDX011-04
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients with Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)

Northwest Georgia Oncology Centers (NGOC) is actively engaged in clinical trials advancing the treatment of breast cancer offered for various stages and types. We divide breast cancers into three main groups based on molecular phenotypes: estrogen receptor positive, HER2 receptor positive and “triple negative” breast cancers.